G. Muller

Publications198
h-index42
Citations9,377
Highly Influential Citations253
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • D. Stirling
  • 162 Publications • 9,812 Citations
  • G. Kaplan
  • 333 Publications • 27,384 Citations
  • K. Anderson
  • 2,381 Publications • 131,298 Citations
  • L. Corral
  • 76 Publications • 5,845 Citations
  • Publications
  • Influence
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
TLDR
The distinct immunomodulatory activities of these classes of thalidomide analogues may potentially allow them to be used in the clinic for the treatment of different immunopathological disorders.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
TLDR
Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.
Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
TLDR
It is suggested that lenalidomide has the potential to enhance the rituximab-induced killing of NHL cell lines and primary B-cell chronic lymphocytic leukemia cells via a NK cell-mediated and monocyte-mediated ADCC mechanism in vitro, providing a strong rationale for the combination of lenalidumide with IgG1 antibodies to target tumor-specific antigens in patients with cancer.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
TLDR
The pharmacological effects of apremilast are consistent with those of a targeted PDE4 inhibitor, with selective effects on innate immune responses and a wide therapeutic index compared to its gastrointestinal side effects.
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
TLDR
The data provide one explanation for adjuvant properties of lenalidomid and pomalidomide and suggest that they may help overcome an important barrier to tumour-specific immunity in cancer patients.
First Report of the Causal Agent of Huanglongbing ("Candidatus Liberibacter asiaticus") in Brazil.
TLDR
The presence of "Ca. L. asiaticus" in Brazil is confirmed for the first time, which relates to the potential damage that this pathogen could cause to the citrus industry in the largest citrus-producing country in the world.
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
TLDR
In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Tristeza control by cross protection: a U.S.-Brazil cooperative success.
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
TLDR
The importance of stromal–MM cell interactions in regulating VEGF and IL-6 secretion is demonstrated, and additional mechanisms whereby thalidomide and IMiD1-CC4047 act against MM cells in the BM millieu are suggested.
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.
TLDR
The 4-amino substituted analogs of thalidomide and its isoindolin-1-one analog were found to be potent inhibitors of TNF-alpha release in LPS stimulated human PBMC.
...
1
2
3
4
5
...